Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) – Equities researchers at Jefferies Financial Group reduced their FY2020 earnings per share (EPS) estimates for shares of Osmotica Pharmaceuticals in a research note issued on Monday, May 13th. Jefferies Financial Group analyst D. Steinberg now forecasts that the company will post earnings per share of ($0.17) for the year, down from their previous estimate of ($0.08). Jefferies Financial Group also issued estimates for Osmotica Pharmaceuticals’ FY2021 earnings at $0.10 EPS, FY2022 earnings at $1.25 EPS and FY2023 earnings at $2.15 EPS.
Several other equities research analysts also recently commented on the stock. Zacks Investment Research raised shares of Osmotica Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Co set a $14.00 price target on Osmotica Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $15.50.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.08). The business had revenue of $57.13 million for the quarter, compared to analyst estimates of $53.58 million.
Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Osmotica Pharmaceuticals during the first quarter valued at about $45,000. American International Group Inc. bought a new stake in shares of Osmotica Pharmaceuticals during the fourth quarter valued at about $50,000. Acadian Asset Management LLC bought a new stake in shares of Osmotica Pharmaceuticals during the first quarter valued at about $52,000. Hancock Whitney Corp bought a new stake in shares of Osmotica Pharmaceuticals during the first quarter valued at about $83,000. Finally, Deutsche Bank AG bought a new stake in shares of Osmotica Pharmaceuticals during the fourth quarter valued at about $111,000. Hedge funds and other institutional investors own 12.78% of the company’s stock.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: Blockchain
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.